Expression of syndecan-1 and cathepsins D and K in advanced esophageal squamous cell carcinoma

Folia Histochemica et Cytobiologica

Volumn 47, Issue 4, 2009, Pages 571-578

  Szumilo, Justyna ^a   Burdan, Franciszek ^a   Zinkiewicz, Krzysztof ^a   Dudka, Jaroslaw ^a   Klepacz, Robert ^a   Dabrowski, Andrzej ^a   Korobowicz, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cathepsin D; Cathepsin K; Esophagus; Immunohistochemistry; Squamous cell carcinoma; Syndecan 1

Indexed keywords

CATHEPSIN D; CATHEPSIN K; SYNDECAN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION;

EID: 77954400771     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0012-8     Document Type: Article

References (42)

1. Wojciechowska U, Didkowska J, Tarkowski W, Zatonski W., Malignant neoplasms in Poland in 2002. National Register of Tumors. Warsaw: Oncology Center - Maria Sklodowska- Curie Institute; 2004.
2. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590-601.
3. Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol. 2005;58:343-351.
4. Aznavoorian S, Murphy AN, Stetler-Stevenson WG et al. Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993;71:1369-1383.
5. Carey DJ. Syndecans: multifunctional cell - surface co-receptors. Biochem J. 1997;327:1-16.
6. Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol. 2004;2:3-14.
7. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest. 2005;52:1-9.
8. Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metastasis: a protease and a ligand. APMIS. 1999;107:86-95.
9. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta 2004;342:41-69.
10. Kleer CG, Bloushtain-Qimron N, Chen YH, et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res. 2008;14:5357-5367.
11. Bühling F, Gerber A, Häckel C et. al. Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol. 1999; 20:612-619.
12. Brubaker KD, Vessella RL, True LD et al. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res. 2003;18:222-230.
13. Rapa I, Volante M, Cappia S et al. Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. Am J Clin Pathol. 2006;125:847-854.
14. Hamilton SR, Aaltonen LA. Pathology and genetics of tumors of the digestive system. WHO Classification of Tumors. Lyon: IARC Press; 2000.
15. Torres CM, Wang HH, Turner JR, et al. Pathologic prognostic factors in squamous cell carcinoma: a follow-up study of 74 patients with or without preoperative chemoradiation therapy. Mod Pathol. 1999;12:961-968.
16. Anttonen A, Kajanti M, Heikkila P et al. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer. 1999;79:558-564.
17. Mukunyadzi P, Liu K, Hanna EY et al. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol. 2003;16:796-801.
18. Rintala M, Inki P, Klmi P et al. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol. 1999;75:372-378.
19. Chu YQ, Ye ZY, Tao HQ et al. Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma. World J Gastroenterol. 2008;4:1990-1996.
20. Hashimoto Y, Skacel M, Adams JC. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer. 2008;8:185-191.
21. Li HG, Xie DR, Shen XM et al. Clinicopathological signifi-cance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol. 2005;14: 1445-1451.
22. Harada K, Masuda S, Hirano M., et al. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol. 2003;34:857-863.
23. Gökden N, Greene GF, Bayer-Garner IB et al. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol. 2006;14:173-177.
24. Hasengaowa J, Kodama J, Kusumoto T et al. Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol. 2005;16:1109-1115.
25. Mikami S, Ohashi K, Usui Y et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinoma. Jpn J Cancer Res. 2001;92:1062-1073.
26. Day RM, Hao X, Ilyas M et al. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch. 1999;434:121-125.
27. Barbareschi M, Maisonneuve P, Aldovini D et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003; 98:474-483.
28. Shariat SF, Svatek RS, Kabbani W et al. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int. 2008;101:232-237.
29. Chen CL, Ou DL. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol. 2006;37:1279-1285.
30. Mylonas I, Makovitzky J, Richter DU et al. Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Acta Histochem. 2003;105:245-252.
31. Ohe H, Tanaka S, Kitadai Y et al. Cathepsin D expression as a possible predictor of lymph node metastasis in submucosal colorectal cancer. Eur J Cancer. 2001;37:180-188.
32. Skrzydlewska E, Sulkowska M, Wincewicz A et al. Evaluation of serum cathepsin B and D in relation to clinicopatho- logical staging of colorectal cancer. World J Gastroenterol. 2005;11:4225-4229.
33. Cheng AL, Huang WG, Chen ZC et al. Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis. J Proteome Res. 2008;7: 2415-2426.
34. Kawasaki G, Kato Y, Mizuno A. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors. Oral Surg Oral Med. Oral Pathol Oral Radiol Endod. 2002;93:446-454.
35. Matsuo K, Kobayashi I, Tsukuba T et al. Immunohistochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells. Hum Pathol. 1996;27:184-190.
36. Merseburger AS, Hennenlotter J, Simon P et al. Cathepsin D expression in renal cell cancer - clinical implications. Eur Urol. 2005;48:519-526.
37. Ioachim E, Tsanou E, Briasoulis E et al. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and met- allothionein in primary invasive breast cancer. Breast. 2003; 12:111-119.
38. Lösch A, Schindl M, Kohlberger P et al. Cathepsin D in ovari- an cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol. 2004;92:545-552.
39. Ikeguchi M, Sakatani T, Ueta T et al. Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma. J Clin Pathol. 2002;55:121-126.
40. Husmann K, Muff R, Bolander ME et al. Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis. Mol Carcinog. 2008;47;66-73.
41. Lindeman JHN, Hanemaaijer R, Mulder A et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol. 2004;165:593-600.
42. Juuti A, Nordling S, Lundin J et al. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 2005;68:97-106.